Clinical trial · Interventional
Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.
Pharmacokinetics, Biodistribution and Targeting of 111 In- Labeled Humanized PAM4IgG in Pre-Surgical Pancreatic Cancer Patients.An Examination of Protein Dose
NCT00364364CI-TRIAL-00036620terminatedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Loss of funding
Summary
Brief summary (as posted)
This no treatment research study is being done to find a safe and an appropriate dose of antibody (protein) against tumor cells to best target the cancer in people with pancreatic cancer. To do this, this no-treatment research study will compare two doses of an antibody called hPAM4 IgG when combined with a radioactive element, Indium-111.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiolabeled humanized PAM4 IgG | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Examine the pharmacokinetics and tumor targeting of 111In-DOTA-hPAM4 anti-MUC-1 IgG given intravenously to patients with known or a suspicion of primary or recurrent pancreatic cancer.
- measure
- An examination of how the pharmacokinetics and tumor targeting are affected by the amount of hPAM4 IgG administered.
- measure
- Targeting with 111In-hPAM4 will be compared to other radiological (e.g., CT) and nuclear (FDG-PET; optional)findings.
- measure
- For patients who undergo surgery after the 111In-hPAM4 study, targeting will be correlated against surgical findings.
Secondary outcomes (5)
- measure
- Correlate tumor targeting, when feasible, with the following:Immunohistology using the hPAM4 antibody
- measure
- Histology,Serum antigen content
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria:- * All patients must either have a histologic or cytological diagnosis of pancreatic cancer or a high clinical suspicion of pancreatic cancer. * Patients must be 21 years of age. * Patients must have measurable disease by CT scan. * Patients must be at least 4 weeks beyond any major surgery. * Patients must be at least 4 weeks beyond any chemotherapy or radiation therapy and must have recovered from treatment-induced toxicity. * Patients must have a performance status of 70% or greater on the Karnofsky Scale and a minimal life expectancy of 3 months. * Patients must not have severe anorexia, nausea or vomiting, and no signs of intestinal obstruction. * Patients must have a serum creatinine that is \< 1.5 x the Institutional Upper Limit of Normal (IULN). * AST/ALT \< 2 times the IULN; serum bilirubin \< 3 x IULN. * WBC 3000/mm3, a granulocyte count 1500/mm3, and a platelet count 100,000/mm3. * Patients must sign an informed consent, and be mentally responsible. There will be no discrimination based on race, creed, or ethnic background. * Patients must be able to return to an approved study site for the scheduled follow-up procedures. Exclusion Criteria: A.Subjects with a significant concurrent medical complication that in the judgment of the Principal Investigator could affect the patient's ability to tolerate or complete this study. These include, but are not restricted to 1. Known history of active coronary artery disease, unstable angina, myocardial infarction, or congestive heart failure present within 6 months or cardiac arrhythmia requiring anti-arrhythmia therapy. 2. Known history of active COPD, or other moderate-to-severe respiratory illness present within 6 months. B. Subjects who have signs of intestinal obstruction. C. Subjects who are pregnant are excluded. D. Subjects who have a measurable antibody response to hPAM4 in their pre-study sample or who are proven allergic upon testing with the agent. E. Patients who are known to have HIV. F. Patients who have a known history of Hepatitis B or C or any other serious liver abnormality will be excluded from enrollment. G. Prisoners or other institutionalized persons. \-
References
Publications (0)
Data not yet available
No reference posted for this study.